Setback for Bharat Biotech, US' Food and Drug Administration rejects Covaxin emergency use approval

In a setback for Bharat Biotech, the US' Food and Drug Administration rejects Covaxin emergency use approval. FDA suggests a biologics license route. US Food and Drug Administration has recommended Ocugen Inc, the US partner of the Indian vaccine maker, to go for Biologics Licence Application (BLA) route with additional data, nixinghopes of Emergency Use Authorisation. BLA is a full approval mechanism by the FDA for drugs and vaccines. TIMES NOW's Sherine brings in a detailed report on this news update. Watch the full video to know more about this story and stay updated with the latest news on Times Now.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting